Regal Intel Receives Two Seed Grants to Test Rare Disease Surveillance Guidelines Against Real Patient Outcomes
Studies in epidermodysplasia verruciformis and Peutz-Jeghers syndrome will measure outcomes for patients whose care rests on expert opinion rather than cohort evidence WARREN, N.J., Nov. 12, 2026 /PRNewswire/ -- Regal Intel, Inc., a 501(c)(3) nonprofit research organization, has received...
Covered in this story
Analyst targets on Intel
- Freedom Broker: at $92.1 · target $90 by Oct 2027 · Hold via Investing.com
- Piper Sandler: at $65.8 · target $90 by Oct 2027 · Neutral via Investing.com
- Stifel: at $65.8 · target $90 by Oct 2027 · Hold via Investing.com
“At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $INTC yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Intel →Dalsna Finance is currently tracking 50 stories mentioning Intel, the earliest published 13 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.